Genentech rejects Roche bid
Friday, 15 August, 2008
A special committee of US biotechnology giant Genentech’s board of directors has rejected a proposal by Swiss pharma Roche to buy out the company for US$43.7 billion.
Roche, which already owns 56 per cent of Genentech, was offering $89 per share for the remaining 44 per cent.
The Genentech directors said the offer undervalued the company but would consider a new proposal at a price it considered worthy.
Genentech’s stocks were trading on the New York Stock Exchange at close to $100 this week.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
